The overall goal of this project is to understand the complex regulatory role of the tissue factor pathway in vascular homeostasis. Arterial thrombosis is initiated when endothelial disruption or injury leads to exposure and activation of subendothelial procoagulants, including tissue factor (TF), to flowing blood. We have focused on tissue factor pathway inhibitor (TFPI) as the major physiologic inhibitor of TF. Locally active TFPI at the luminal surface of endothelium provides a nonthrombogenic surface in the unperturbed state. TFPI, a Kunitz-type serine-protease inhibitor, uniquely modifies the coagulation cascade in vivo by binding to TF-factor Vila (via the K1 domain) and factor Xa (via the K2 domain) forming an inhibitory complex which dampens further coagulation. However, if local levels of TFPI are not adequate to dampen local TF activity, thrombosis continues. TFPI, via proposed direct effects and indirectly via its anticoagulant properties, also influences vascular structure. Our objective is to define the role of the endothelium in this process. Locally active TFPI may be derived from vascular cells or from the circulation. Endothelial cells may play at least two roles in these processes: as a site of TFPI action and as an accessible source of local and circulating forms. These functions may vary in distinct vascular beds. Recent clinical studies indicate an association between low circulating TFPI levels and increased vascular risk. The focus of this proposal is to delineate the role of endothelial-derived TFPI in regulating the homeostatic balance between TF and TFPI and its resultant effects on macro- and micro-vascular structure, function and thrombosis in multiple vascular beds. Our underlying hypothesis is that endothelial production of TFPI regulates circulating and local TFPI levels which modulate micro- and macro-vascular function and thrombosis during development and in adults.
Three specific aims are proposed.
Specific Aim 1 : To determine the effects of endothelial-specific gene deletion of TFPI on murine development and hemostasis.
Specific Aim 2 : To define the role of endothelial-derived TFPI on vascular thrombosis.
Specific Aim 3 : To define the role of endothelial-derived TFPI on vascular remodeling including angiogenesis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL065191-07
Application #
7111851
Study Section
Atherosclerosis and Inflammation of the Cardiovascular System Study Section (AICS)
Program Officer
Ganguly, Pankaj
Project Start
2000-09-05
Project End
2010-07-31
Budget Start
2006-08-01
Budget End
2007-07-31
Support Year
7
Fiscal Year
2006
Total Cost
$363,746
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Holroyd, Eric W; Delacroix, Sinny; Larsen, Katarina et al. (2012) Tissue factor pathway inhibitor blocks angiogenesis via its carboxyl terminus. Arterioscler Thromb Vasc Biol 32:704-11
Holroyd, Eric W; White, Thomas A; Pan, Shuchong et al. (2012) Tissue factor pathway inhibitor as a multifunctional mediator of vascular structure. Front Biosci (Elite Ed) 4:392-400
White, Thomas A; Johnson, Tucker; Zarzhevsky, Natalia et al. (2010) Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis. Blood 116:1787-94
White, Thomas A; Pan, Shuchong; Witt, Tyra A et al. (2010) Murine strain differences in hemostasis and thrombosis and tissue factor pathway inhibitor. Thromb Res 125:84-9
Holroyd, Eric W; Simari, Robert D (2010) Interdependent biological systems, multi-functional molecules: the evolving role of tissue factor pathway inhibitor beyond anti-coagulation. Thromb Res 125 Suppl 1:S57-9
White, Thomas A; Witt, Tyra A; Pan, Shuchong et al. (2010) Tissue factor pathway inhibitor overexpression inhibits hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol 43:35-45
Pan, Shuchong; White, Thomas A; Witt, Tyra A et al. (2009) Vascular-directed tissue factor pathway inhibitor overexpression regulates plasma cholesterol and reduces atherosclerotic plaque development. Circ Res 105:713-20, 8 p following 720
Sharma, Deepak K; Brown, Jennifer C; Choudhury, Amit et al. (2004) Selective stimulation of caveolar endocytosis by glycosphingolipids and cholesterol. Mol Biol Cell 15:3114-22
Gulati, Rajiv; Simari, Robert D (2004) Autologous cell-based therapies for vascular disease. Trends Cardiovasc Med 14:262-7
Gulati, Rajiv; Jevremovic, Dragan; Witt, Tyra A et al. (2004) Modulation of the vascular response to injury by autologous blood-derived outgrowth endothelial cells. Am J Physiol Heart Circ Physiol 287:H512-7

Showing the most recent 10 out of 16 publications